ViroPharma's Second Act: First a Tough One to Follow

In the year since biotech ViroPharma acquired Vancocin, it's transformed itself from a development-style biotech into an earnings-driven success. One result: a new shareholder base that likes regular profit increases and may not tolerate the lower margins that come with additional R&D spending or in-licensing costs. But with generics and other competitors on the near-term horizon, ViroPharma needs a dramatic second-act solution.

By Ellen Foster Licking

Just last fall, ViroPharma Inc. was in desperate circumstances. Its first product had failed to win approval from the...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo